Effect of α-Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer Prevention

Abstract

Polyamine levels in rectal mucosa can be continuously suppressed by daily oral doses of DFMO that produce few or no side effects. A dose of 0.20 g/m2 can be used safely in combination phase IIb or single-agent phase III chemoprevention trials.